QIAGEN Launches QIAsure Methylation Test to Determine Cervical Cancer Risk
New follow-up assay helps stratify patients with transforming HPV infections
New follow-up assay helps stratify patients with transforming HPV infections
Novel Coronavirus 2019-nCoV (SARS-CoV-2) Spike Glycoprotein (S1) is a recombinant antigen which contains the Spike protein amino acids 1-674. Spike S1 protein is manufactured in HEK293 mammalian cells, ensuring the most authentic post-translational modifications.
Novel Coronavirus 2019-nCoV (SARS-CoV-2) Spike Glycoprotein (S2) is a recombinant antigen which contains the Spike S2 protein, amino acids 685-1211. Spike S2 is manufactured in mammalian HEK293 cells to ensure the most authentic post-translational modifications.
New blood test provides a unique new framework for early detection of the most common cancers
With abundant data on plants, large animals and their activity, and carbon soil levels in the Amazon, Stanford research suggests that large animal diversity influences carbon stocks and contributes to climate change mitigation
SARS-CoV-2 Spike Glycoprotein (S2) is a recombinant antigen which contains the Spike protein amino acids 685-1211 of subunit 2. Spike S2 protein is manufactured to high yield and purity using the Native Antigens baculovirus-insect cell platform. SARS-CoV-2, previously known as the 2019 Novel Coronavirus (2019-nCoV), causes the pandemic COVID-19 disease.
Chromatographic method development factors, parameters and strategies
A look at some of the available companion diagnostics for breast, lung and colorectal cancer
Chromatography experts share how the latest 2D-LC technology can benefit your pharmaceutical, food, or polymer analysis applications and more
Read this exclusive interview with Louise Kenny, one of the founding directors of the INFANT Centre, to discover how they are using mass spectrometry to research preeclampsia and pre-term birth
Dr. Josephine Bunch, UK Grand Challenge awardee, describes her unprecedented research into a tumor’s intricate architecture and shares her ultimate goal of mapping what’s inside a tumor
AEOL 10150 is currently the only drug being developed by BARDA to address the delayed effects of radiation exposure